

# Anne Moscona

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3255890/publications.pdf>

Version: 2024-02-01

31  
papers

1,955  
citations

516710

16  
h-index

434195

31  
g-index

72  
all docs

72  
docs citations

72  
times ranked

4037  
citing authors

#	ARTICLE	IF	CITATIONS
1	A three-dimensional model of human lung development and disease from pluripotent stem cells. <i>Nature Cell Biology</i> , 2017, 19, 542-549.	10.3	467
2	Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. <i>Nature Immunology</i> , 2021, 22, 25-31.	14.5	403
3	In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. <i>PLoS Biology</i> , 2020, 18, e3000849.	5.6	225
4	Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. <i>Science</i> , 2021, 371, 1379-1382.	12.6	158
5	Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry. <i>PLoS Pathogens</i> , 2010, 6, e1001168.	4.7	115
6	A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity. <i>PLoS ONE</i> , 2012, 7, e36833.	2.5	67
7	Inhibition of Coronavirus Entry <i>In Vitro</i> and <i>Ex Vivo</i> by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. <i>MBio</i> , 2020, 11, .	4.1	63
8	Measles Fusion Machinery Is Dysregulated in Neuropathogenic Variants. <i>MBio</i> , 2015, 6, .	4.1	45
9	Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. <i>Scientific Reports</i> , 2017, 7, 43610.	3.3	45
10	Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, 218-227.	4.0	45
11	Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. <i>Nature Communications</i> , 2021, 12, 5809.	12.8	37
12	Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. <i>Scientific Reports</i> , 2017, 7, 45647.	3.3	36
13	Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation. <i>MBio</i> , 2018, 9, .	4.1	27
14	Analysis of a Subacute Sclerosing Panencephalitis Genotype B3 Virus from the 2009-2010 South African Measles Epidemic Shows That Hyperfusogenic F Proteins Contribute to Measles Virus Infection in the Brain. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
15	Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived Fusion Protein Is Pathogenic after Infection via the Respiratory Route. <i>Journal of Virology</i> , 2019, 93, .	3.4	24
16	Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent. <i>Journal of the American Chemical Society</i> , 2019, 141, 12648-12656.	13.7	21
17	The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell-derived lung progenitors in 3D. <i>Nature Protocols</i> , 2021, 16, 1802-1829.	12.0	21
18	Features of Circulating Parainfluenza Virus Required for Growth in Human Airway. <i>MBio</i> , 2016, 7, e00235.	4.1	18

#	ARTICLE	IF	CITATIONS
19	Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection. <i>Journal of the American Chemical Society</i> , 2021, 143, 5958-5966.	13.7	14
20	Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length. <i>Molecules</i> , 2017, 22, 1190.	3.8	13
21	Structure-“Stability”-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles. <i>ACS Nano</i> , 2018, 12, 9855-9865.	14.6	13
22	Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces. <i>PLoS Pathogens</i> , 2020, 16, e1008883.	4.7	12
23	Structure-Guided Improvement of a Dual HPIV3/RSV Fusion Inhibitor. <i>Journal of the American Chemical Society</i> , 2020, 142, 2140-2144.	13.7	11
24	Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein. <i>ACS Nano</i> , 2021, 15, 12794-12803.	14.6	9
25	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. <i>MBio</i> , 2022, 13, .	4.1	9
26	Effects of Single $\pm$ -to- $\mp$ Residue Replacements on Recognition of an Extended Segment in a Viral Fusion Protein. <i>ACS Infectious Diseases</i> , 2020, 6, 2017-2022.	3.8	8
27	Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets. <i>MBio</i> , 2022, 13, e0383121.	4.1	5
28	Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds. <i>Viruses</i> , 2022, 14, 1186.	3.3	4
29	Parainfluenza virus entry at the onset of infection. <i>Advances in Virus Research</i> , 2021, 111, 1-29.	2.1	3
30	Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model. <i>Thrombosis Research</i> , 2022, 210, 6-11.	1.7	3
31	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. <i>MSphere</i> , 2021, 6, e0057121.	2.9	2